A little history
myNEO was founded in 2018 by leading biotech entrepreneurs combining expertise from different academic institutions. Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge have since then expanded the team with established domain in antigen discovery experts as well as ambitious talent to further grow the company's innovation and developments.
To date, myNEO has achieved several pivotal milestones in realizing its vision. These include:
- Development of state-of-the-art antigen prediction algorithms
- Discovery of novel, dark antigen targets called camyotopes
- (Co-)development of novel immunotherapeutics products via strategic collaborations or in-house, leading to 3 separate programs executing successful IND/CTA filings in 2025
- The publication of high-impact scientific papers
- ISO and regulatory approval for clinical use of technology
- Securing valuable intellectual property with multiple patents
- Receiving several prestigious awards (Most Disruptive Innovator, Forbes 30under30, Rising Star Fast50)
The people behind myNEO
Team
Cedric Bogaert
Chief Executive Officer & Co-founder
Bert Coessens PhD
Chief Operating Officer
Bruno Fant PhD
Chief Scientific Officer
Lien Lybaert PhD
Chief Development Officer
Lore Van Oudenhove
Chief Technology Officer
Lena Pfitzer
Senior data scientist
Gitta Boons PhD
Senior data scientist
Manon Montyne
Principal data scientist
Jens De Ceukeleire
Principal data scientist
Emiel Evenepoel
Junior bioinformatician
Marie Van Hecke PhD
Junior bioinformatician
Sofie Pontzeele
Executive assistant
Lien Lybaert PhD
Chief Development Officer
Lien studied pharmaceutical sciences where she focused on targeted cancer therapy in her master thesis. After her studies, she did an IWT-funded PhD in the lab of Biopharmaceutical Technology of Prof. Bruno De Geest at Ghent University where she focused on the design of immune-modulating generic polymeric strategies for personalized cell-based cancer vaccination.
During her PhD she went abroad as FWO-funded visiting researcher in the lab of Prof. Aaron Esser-Kahn at the University of California, Irvine where she researched TLR-ligand adjuvant functionalization of cancer vaccines. She published seven first-author A1 publications and is co-author on multiple different scientific papers.
Lien has profound expertise in the immune-oncology field and in-depth knowledge of tumor immuno-biology and therapeutic strategies. As CDO, Lien leads the camyotope™ drug development department of myNEO.